Curiel DT - Search Results

1

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W. Curiel TJ, et al. Among authors: curiel dt. Nat Med. 2003 May;9(5):562-7. doi: 10.1038/nm863. Epub 2003 Apr 21. Nat Med. 2003. PMID: 12704383

2

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ. Zou W, et al. Among authors: curiel tj, curiel dt. Nat Med. 2001 Dec;7(12):1339-46. doi: 10.1038/nm1201-1339. Nat Med. 2001. PMID: 11726975

3

Tumor immunotherapy: inching toward the finish line.

Curiel TJ, Curiel DT. Curiel TJ, et al. Among authors: curiel dt. J Clin Invest. 2002 Feb;109(3):311-2. doi: 10.1172/JCI15042. J Clin Invest. 2002. PMID: 11827989 Free PMC article. No abstract available.

4

Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection.

Zou W, Borvak J, Wei S, Isaeva T, Curiel DT, Curiel TJ. Zou W, et al. Among authors: curiel tj, curiel dt. Eur J Immunol. 2001 Dec;31(12):3833-9. doi: 10.1002/1521-4141(200112)31:12<3833::aid-immu3833>3.0.co;2-y. Eur J Immunol. 2001. PMID: 11745405 Free article.

5

Conditionally replicative adenoviruses for ovarian cancer therapy.

Barnes MN, Coolidge CJ, Hemminki A, Alvarez RD, Curiel DT. Barnes MN, et al. Among authors: curiel dt. Mol Cancer Ther. 2002 Apr;1(6):435-9. Mol Cancer Ther. 2002. PMID: 12477056 Review.

6

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. Barker SD, et al. Among authors: curiel dt. J Gene Med. 2003 Apr;5(4):300-10. doi: 10.1002/jgm.341. J Gene Med. 2003. PMID: 12692864

7

Cancer gene therapy and immunotherapy.

Kawakami Y, Curiel TJ, Curiel DT. Kawakami Y, et al. Among authors: curiel tj, curiel dt. Cancer Chemother Biol Response Modif. 2003;21:327-37. doi: 10.1016/s0921-4410(03)21016-4. Cancer Chemother Biol Response Modif. 2003. PMID: 15338753 Review. No abstract available.

8

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Hemminki A, et al. Among authors: curiel dt. Hum Gene Ther. 2002 Aug 10;13(12):1505-14. doi: 10.1089/10430340260185139. Hum Gene Ther. 2002. PMID: 12215271 Clinical Trial. No abstract available.

9

Gene therapy for ovarian cancer: progress and potential.

Kirby TO, Curiel DT, Alvarez RD. Kirby TO, et al. Among authors: curiel dt. Hematol Oncol Clin North Am. 2003 Aug;17(4):1021-50. doi: 10.1016/s0889-8588(03)00055-8. Hematol Oncol Clin North Am. 2003. PMID: 12959190 Review.

10

A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients.

Alvarez RD, Curiel DT. Alvarez RD, et al. Among authors: curiel dt. Hum Gene Ther. 1997 Mar 20;8(5):597-613. doi: 10.1089/hum.1997.8.5-597. Hum Gene Ther. 1997. PMID: 9095411 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

685 results

Search Page

Filters